Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis

NCT02439307 is registered in ClinicalTrials.gov with Coordinación de Investigación en Salud, Mexico as lead sponsor.

NCT NCT02439307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02439307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis
Lead sponsor
Coordinación de Investigación en Salud, Mexico
Phase
Not applicable
Overall status
Terminated
Start date
February 28, 2017
Completion date
July 26, 2021
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cirrhosis, small intestinal bacterial overgrowth